Since we have demonstrated that MDSCs and regulatory T cells express IL‐13Rα2,64 it is possible that CAR‐T cells with a high binding targeting structure (scFv‐IL‐13Rα2 as a payload) will have a better chance of demonstrating a robust anti‐tumour effect. Here, IL13RA2 is linked to neoplasm.